25 March 2022 - - US-based IVD manufacturer Applied BioCode has appointed Chris Bernard as their new chief executive officer, the company said.

Bernard joins as Applied BioCode continues to expand its US commercial footprint and explores US and global expansion and new opportunities for their technology.

With its current portfolio of PCR-based, multiplex molecular diagnostic tests in the respiratory and gastrointestinal markets, along with the new SARS-CoV-2 Flu Plus Assay EUA approval, the company is continuing to scale its commercial business in providing transformative solutions for high throughput molecular diagnostics.

Bernard brings 27 years of commercial, operational, and R and D leadership experience in diagnostics and medical devices to Applied BioCode.

Most recently Chris was CEO of Oncogenesis Inc., a startup in oncology diagnostics, and Curetis USA Inc., (Opgen Inc.), a multiplex, infectious disease diagnostic company.

He also has held various commercial executive roles at Epic Sciences Inc., Metabolon Inc., Abaxis Inc. (Zoetis Inc.), and Cytyc Corp (Hologic Inc.). His extensive experience will be key in evaluating current and emerging opportunities as the company enters its next phase of commercial expansion.

Applied BioCode is an IVD manufacturer that designs, develops, and commercializes multiplex testing products. The company has combined "digital barcodes" with immuno- and molecular chemistry to create a new, bio-inspired Barcoded Magnetic Bead Technology.

The micro BMBs, about the diameter of a human hair, are tagged with immunochemistry or molecular probes, allowing the digital barcodes to be easily scanned and accurately identified up to 4,096 barcodes with no ambiguity for biological targets.

The company has FDA 510(k) clearances for their 17-plex Respiratory Pathogen Panel and 17-plex Gastrointestinal Pathogen Panel based on their BioCode MDx-3000 automated system.

The GPP and RPP are CE-Marked for use in European countries conforming to CE-Mark regulations. Applied BioCode, Inc. has also been granted an Emergency Use Authorization from the US FDA for its BioCode SARS-CoV-2 Flu Plus Assay, BioCode SARS-CoV-2 Assay, and an additional EUA for Pooled COVID-19 Testing.

Applied BioCode also partners with a variety of diagnostic companies with applications that include the infectious disease, autoimmune disease, allergy, gut microbiome, and veterinary markets.